Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 10/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714550 | 1.00 | YTHDC1 (0.63) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL19714548 | 0.87 | YTHDC1 (0.59) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL17815585 | 0.87 | YTHDC1 (0.59) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL19714686 | 0.87 | YTHDC1 (0.55) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL17815586 | 0.87 | YTHDC1 (0.55) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL17815788 | 0.84 | CFTR (0.62) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL19714626 | 0.84 | CFTR (0.62) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL17815605 | 0.79 | HDAC6 (0.62) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL17815602 | 0.78 | CCNE2 (0.64) | YTHDC1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL27387465 | 0.78 | YTHDC1 (1.00) | YTHDC1HDAC1HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | YTHDC1 3944/4885HDAC1 1527/4885HDAC2 1700/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | YTHDC1 3944/4885HDAC1 1527/4885HDAC2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.